1. Cytomegalovirus-induced stomatitis in a patient with refractory diffuse large B-cell lymphoma

   • Masahiro Manabe
   • Takahide Kondo

   Images in Hematology 03 April 2023 Pages: 629 - 630

   

2. Guest Editorial: what can be done to improve cancer immunotherapies?

   • Hideto Tamura

   Progress in Hematology 25 March 2023 Pages: 631 - 633

3. Resilient T-cell responses in patients with advanced cancers

   • Joanina K. Gicobi
   • Emilia R. Dellacecca
   • Haidong Dong

   Progress in Hematology 21 July 2022 Pages: 634 - 639

   

4. Extracellular vesicle-mediated immunoregulation in cancer

   • Tomofumi Yamamoto
   • Yusuke Yamamoto
   • Takahiro Ochiya

   Progress in Hematology 11 August 2022 Pages: 640 - 646

   

5. Novel technologies for improving the safety and efficacy of CAR-T cell therapy

   • Keisuke Ohta
   • Yukimi Sakoda
   • Koji Tamada

   Progress in Hematology 29 October 2022 Pages: 647 - 651

   

6. Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy

   • Brian M. Russell
   • David E. Avigan

   Progress in Hematology 25 March 2023 Pages: 652 - 659

   

7. Decision analysis of allogeneic bone marrow transplantation versus immunosuppressive therapy for young adult patients with aplastic anemia

   • Yoshinobu Kanda
   • Kensuke Usuki
   • Hirohito Yamazaki

   Original Article 03 January 2023 Pages: 660 - 668

   

8. High levels of factor VIII activity in patients with acquired hemophilia A in remission are associated with unusually low coagulation potentials

   • Fumitaka Shibasaki
   • Masahiro Takeyama
   • Keiji Nogami

   Original Article 06 January 2023 Pages: 669 - 677

   

9. Factor XII deficiency: a clinical and molecular genetic study

   • Ekaterina Demidova
   • Valentina Salomashkina
   • Vadim Surin

   Original Article 10 January 2023 Pages: 678 - 683

   

10. Fetal hemoglobin level predicts lower-risk myelodysplastic syndrome

    • Ryujiro Hara
    • Toshihiko Kitahara
    • Kiyoshi Ando

    Original Article 27 December 2022 Pages: 684 - 693

    

11. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study

    • Chikashi Yoshida
    • Hiroki Yamaguchi
    • the Kanto CML Study Group

    Original Article Open access 04 February 2023 Pages: 694 - 705

    

12. A comprehensive overview of AL amyloidosis disease characteristics accumulated over two decades at a single referral center in Korea

    • Sang Eun Yoon
    • Darae Kim
    • Kihyun Kim

    Original Article 27 December 2022 Pages: 706 - 717

    

13. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice

    • Makiko Mizuguchi
    • Yasunobu Okamoto
    • Shuji Ozaki

    Original Article 24 January 2023 Pages: 718 - 728

    

14. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma

    • Daisuke Minakata
    • Tadao Ishida
    • Kenshi Suzuki

    Original Article Open access 24 January 2023 Pages: 729 - 737

    

15. Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL

    • Yasushi Onishi
    • Eijiro Furukawa
    • Hideo Harigae

    Original Article 09 February 2023 Pages: 738 - 747

    

16. Synergistic effect of combined PI3 kinase inhibitor and PARP inhibitor treatment on BCR/ABL1-positive acute lymphoblastic leukemia cells

    • Haruka Hiroki
    • Koshi Akahane
    • Masatoshi Takagi

    Original Article 28 December 2022 Pages: 748 - 758

    

17. Optimal timing of liver transplantation for liver cirrhosis caused by sclerosing cholangitis in a patient with Langerhans cell histiocytosis: a case report

    • Mai Watakabe
    • Kohei Fukuoka
    • Katsuyoshi Koh

    Case Report 05 December 2022 Pages: 759 - 764

    

18. Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T

    • Sai Ambati
    • Bazga Ali
    • Jonathan Underwood

    Case Report Open access 09 February 2023 Pages: 765 - 768

    

19. Development of Epstein–Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma

    • Mina Yoshida
    • Ken Morita
    • Mineo Kurokawa

    Case Report 13 December 2022 Pages: 769 - 773

    

20. Long-term efficacy and safety profile of splenectomy for pediatric chronic immune thrombocytopenia

    • Kyohei Isshiki
    • Makiko Mori
    • Katsuyoshi Koh

    Case Report 09 January 2023 Pages: 774 - 780

    

21. Lineage switch in a pediatric patient with KMT2A-MLLT3 from acute megakaryoblastic leukemia to T cell acute lymphoblastic leukemia at the fourth relapse after allo-HSCT: with literature review

    • Li Gao
    • Jun Lu
    • Shaoyan Hu

    Case Report 06 December 2022 Pages: 781 - 785

    

22. Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1)

    • Hideki Nakayama
    • Chitose Ogawa
    • Keizo Horibe

    Correction 21 March 2023 Pages: 786 - 786